IFNA2 and chronic myelogenous leukemia, BCR-ABL1 positive: A pilot phase II study of GM-CSF and IFN-α-2b, in patients with relapsed disease (including AML, blast phase CML, and MDS) after allo-HSCT, was conducted (NCT00548847), and results are pending.